Emerging treatments
Betrixaban
Betrixaban, a direct factor Xa inhibitor, has been approved by the Food and Drug Administration for the prophylaxis of venous thromboembolism (VTE) in adults (with restricted mobility and other risk factors for VTE) hospitalized for an acute illness. It has not been studied for PE therapy, nor treatment of any VTE.
Use of this content is subject to our disclaimer